Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2022-03-18
Target enrollment:
Participant gender:
Summary
The study will assess the effect of anti-diarrhea drug Montmorillonite Power or Loperamide on
the single dose pharmacokinetic parameters of pyrotinib in healthy Chinese subjects. The
safety of pyrotinib alone and when co-administered with each drug will also be assessed.